Prognostic Factors in Operable Breast Cancer Treated with Neoadjuvant Chemotherapy: Towards a Quantification of Residual Disease

Publisher： Karger

E-ISSN： 1423-0232|88|5|261-272

ISSN： 0030-2414

Source： Oncology, Vol.88, Iss.5, 2015-01, pp. : 261-272

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer

By  

ANZ JOURNAL OF SURGERY, Vol. 85, Iss. 5, 2015-05 ,pp. : 315-320

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-04 ,pp. : 213-219

Karger

Access to resources Recommend Favorite

Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 116, Iss. 8, 2017-12 ,pp. : 1021-1028

John Wiley & Sons Inc

Access to resources Recommend Favorite

The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 112, Iss. 6, 2015-11 ,pp. : 597-602

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer

By  

Oncology, Vol. 69, Iss. 6, 2006-02 ,pp. : 478-485

Karger

Access to resources Recommend Favorite